Monument Therapeutics

Monument Therapeutics

Private
ManchesterHealthcare & Life Scienceshttps://monumenttx.com/

Last Round

VC Round

Feb 25, 2025

Est. Valuation

$10.91M

Total Funding Raised

$3.64M

Momentum Score

50 /100

Company Overview

Monument Therapeutics is a biotechnology company that develops novel drugs for serious diseases of the central nervous system by using proprietary digital biomarkers to identify patients with homogenous underlying neurobiology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Mental Health, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Application

Keywords

precision neurosciencedigital biomarkerspatient stratificationCNS drug developmentneurotherapeuticsschizophrenia treatmentneurotechAI patient stratificationCognitive Impairment Associated with SchizophreniaCIASstratified medicineclinical trial optimizationneuroinflammationpostoperative cognitive dysfunctionfixed-dose combination drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Monument Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Monument Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundFeb 25, 2025
VC RoundOct 15, 2024
VC RoundApr 18, 2024
SeedJul 1, 2021

Key People

Founding team and executive leadership

Jenny Barnett

CEO

Executive Team

Monument Therapeutics Investors

Notable investors and investment history

InvestorRounds
ACF InvestorsVC Round
Cambridge AngelsVC Round
o2h venturesSeed, VC Round
Innovate UKVC Round
Catapult VenturesSeed
Neo Kuma VenturesSeed
Wren CapitalSeed, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Monthly visitors grew 2328% MoM to 5.4K.

  • Feb 25, 2025

    $1.07M round led by ACF Investors.

Monument Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Monument Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Monument Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersManchester
Employee Range7
Year Founded2021
Last FundingFeb 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.